Main clinical and laboratory data of the whole sample (patients developing allopurinol-related cutaneous adverse reactions) and of those who showed after switching to febuxostat
| Skin reaction with allopurinol (n=67) | Skin reaction with febuxostat (n=10) | |
| Age, in years | 71.0 (59.8–79.5) | 65.0 (54.8–69.0) |
| Males, n (%) | 49 (73.1%) | 5 (50%) |
| Type of reaction, n (%) | ||
| Non-specific | 55 (82.1%) | 8 (80%) |
| Maculopapular | 9 (13.4%) | 1 (10%) |
| SJS | 3 (4.5%) | 1 (10%) |
| Glomerular filtration rate, in mL/min | 67.0 (44.9–89.3) | 78.8 (42.8–90.6) |
| Serum urate, in mg/dL | 8.4 (7.8–9.9) | 8.1 (5.1–9.9) |
| Starting dose, in mg/day | 100 (range 50–300) | 80 (40–80) |
| Dose at time of CAR, in mg/day | 300 (138–300) | 10 (n=1), 40 (n=4), 80 (n=5) |
Data shown as median (IQR), unless otherwise specified.
CAR, cutaneous adverse reaction; SJS, Stevens-Johnson syndrome.